news
Corning to introduce new dissolvable microcarriers for improved large-scale cell expansion
Corning to unveil new product offerings at Cell & Gene Therapy World in Miami, Fla.
List view / Grid view
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
news
Research enables screening millions of human antibodies for new drug discovery
Researchers have outlined a pioneering method of screening a person’s diverse set of antibodies for rapid therapeutic discovery.
news
Drugs targeting the cells circadian rhythm offers hope for glioblastoma
An experimental drug demonstrated selective cancer-killing ability against breast, colon, leukaemia, brain and melanoma cancer cells with no apparent effects on normal cells...
news
Promising preclinical drug candidate suppresses HIV
A team of researchers have tested a chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose...
news
Anti-obesity drug shrinks fat without suppressing appetite
Researchers have discovered a drug that has been shown to selectively shrink excess fat by increasing fat cell metabolism...
article
Rational drug design: How far have we come?
From the early use of Hansch parameters and Topliss Trees to today’s computational structure–activity techniques, medicinal chemists have long sought to rationalise drug design to find the quickest and most resource-efficient route to market. But while modern strategies are more reliant on statistical algorithms and vast data libraries, these founding…
news
Thorase protein may be linked to schizophrenia
Epilepsy drug reverses anti-social behaviours in mice with genes that produce variant proteins...
product
Alpha technology
3 January 2018 | By PerkinElmer
Alpha (Amplified Luminescence Proximity Homogeneous Assay) bead-based technology for no-wash assays.
news
A2aAR protein holds clues for better drug design
Scientists have investigated a key protein used in drug design and discovered dynamic structural features that may lead to new ways to target diseases...
news
MG1 virus destroys HIV-infected cells that standard therapies can’t reach
Researchers from Canada try a new approach to eliminate dormant HIV-infected cells from the body using the MG1 virus.
article
Expert view: Conquering late stage failures with advanced hit-to-lead techniques
Failing early in drug discovery is the primary driving force for new techniques in the hit-to-lead phase.
article
Patient-derived neural progenitor cells as a drug discovery model for mitochondrial diseases
Mitochondrial DNA (mtDNA) mutations cause severe disorders that are untreatable and mostly affect the nervous system. The difficulty in funding therapies may also be explained by the lack of viable modelling systems...
article
Expert view: Optimising the hit-to-lead workflow
Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.
article
Using bioinformatics sequence similarities to optimise repurposing activities
A significant amount of selectivity and potency data originating from screening of drug targets is generated each year and deposited in public databases. This can be exploited to accelerate drug discovery, in particular, for a variety of repurposing activities...
article
Expert view: Addressing the big challenges in drug screening
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.
